Always double-check the most current FDA label or corporate press release indications, titrations, and payer coverage are changing rapidly.) FDA-Approved Medications and Indications (As of Fall 2025) Lets start with a quick rundown of the major players Ozempic, Wegovy, Mounjaro, and Zepbound and what theyre actually approved to treat: Ozempic (semaglutide injection) Type 2 diabetes mellitus, adjunct to diet and exercise To reduce major adverse cardiovascular events (MACE: Cardiovascular death, nonfatal myocardial infarction, stroke) in adults with Type 2 diabetes mellitus and established cardiovascular disease Approved (Jan 2025) to reduce the risk of chronic kidney disease progression and cardiovascular death in Type 2 Diabetes mellitus and chronic kidney disease Rybelsus (oral semaglutide) Type 2 Diabetes mellitus, adjunct to diet and exercise To reduce major adverse cardiovascular events (MACE: Cardiovascular death, nonfatal myocardial infarction, stroke) in patients with Type 2 Diabetes at high risk for MACE Mounjaro (tirzepatide injection) Type 2 Diabetes mellitus, adjunct to diet and exercise No current FDA indication for weight loss or cardiovascular disease prevention (though trials are ongoing) Wegovy (semaglutide injection, higher max dose for weight loss) Chronic weight management in: - Adults with obesity (BMI 30) - Adults with overweight (BMI 27) plus at least one weight-related comorbidity To reduce the risk of major adverse cardiovascular events in adults with obesity or overweight and established cardiovascular disease Recently approved for noncirrhotic metabolic-associated steatohepatitis (with F2F3 fibrosis) in adults Zepbound (tirzepatide for weight loss) Chronic weight management in adults with obesity or overweight, plus at least one comorbidity Moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity Insurance Coverage Realities Even when the indications are met, insurance coverage for GLP-1s isnt guaranteed
Zepbound is part of a medication class called dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonists
Interestingly, L585 could only be replaced with an amino acid having similar physiochemical properties, including isoleucine, methionine, and valine, without negatively affecting FcRn binding 64
The 10% weight loss guarantee adds a layer of accountability you dont see often
10.1111/dom.13162 3 ArthurJ
